Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | XIAP | P98170 | 2/20 | 0.41 |
| ▸ | MLX | Q9UH92 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 8/20 | 0.40 |
| ▸ | CMA1 | P23946 | 1/20 | 0.39 |
| ▸ | CALCRL | Q16602 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1404290 | 1.00 | ACE (0.41) | ACEXIAPMLXELANECMA1 | |
| SCHEMBL1404295 | 1.00 | ACE (0.41) | ACEXIAPMLXELANECMA1 | |
| SCHEMBL23229943 | 0.97 | ACE (0.39) | ACEXIAPMLXELANECMA1 | |
| SCHEMBL29411315 | 0.96 | XIAP (0.42) | ACEXIAPMLXELANECMA1 | |
| Trifluoroacetic Acid SCHEMBL30641540 | 0.95 | ELANE (0.44) | ACEXIAPMLXELANECMA1 | |
| SCHEMBL30102197 | 0.94 | XIAP (0.41) | ACEXIAPMLXELANECMA1 | |
| SCHEMBL23230066 | 0.93 | XIAP (0.45) | ACEXIAPMLXELANECMA1 | |
| SCHEMBL23230061 | 0.93 | XIAP (0.45) | ACEXIAPMLXELANECMA1 | |
| SCHEMBL664013 | 0.92 | ELANE (0.47) | ACEXIAPMLXELANECMA1 | |
| SCHEMBL664014 | 0.92 | ELANE (0.47) | ACEXIAPMLXELANECMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210106506-A1 | METHODS FOR COSMETIC SKIN REMODELING | ELC MANAGEMENT LLC | 2021-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210106506-A1 | METHODS FOR COSMETIC SKIN REMODELING | CUTA, PLOD3, KRT18 | ACE 4849/4885XIAP 3185/4885MLX 4307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.